Imaging Test for Neuroblastoma in Children Compared With Standard Scan
Tests a PET scan tracer, 68Ga-DOTATATE, against standard imaging in children with neuroblastoma.
Plain-language title generated from the registry record
Registry title: 68Ga-DOTATATE Neuroblastoma Imaging Pilot
Key facts
- Where
- Montreal and Sherbrooke, CanadaSee the 3 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for babies, children and young adults up to 21 years old with suspected, proven or returned neuroblastoma who are already planned for a 123I-MIBG scan. It tests a 68Ga-DOTATATE PET/CT scan.
- Age
- From 1 day to 21 years old.
- Sex
- All sexes can join.
- Disease stage
- Newly suspected or biopsy-proven neuroblastoma, or neuroblastoma that has come back.
- Earlier treatment
- People cannot be under treatment now. No medical or surgical procedure on the tumour between the 123I-MIBG scan and the 68Ga-DOTATATE PET/CT scan.
Main reasons for not taking part
- Another cancer in the past 5 years (except non-melanomatous skin cancer)
- Currently in a randomized controlled trial with unknown allocation
- Currently under treatment
- Medically unstable or unable to have the scan
- Pregnancy, or a past allergic reaction to somatostatin analogues
Read by machine on 12 November 2026.
Where in Canada
- CHU Ste-JustineMontreal, CanadaContact: Marie GalopinTaking people
- McGill University Health Center - Children's hospitalMontreal, CanadaContact: Amelie Tetu, MScNo longer taking part
- CIUSSS de l'Estrie- CHUS HospitalSherbrooke, CanadaContact: Etienne Croteau, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke
- Trial code
- NCT04559217
- Record updated
- 27 May 2026
- Original description
Neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of approximately 10.2 per million children. Staging of the disease can be done by different imaging strategies (CT, MRI, scintigraphy and PET/CT). Discrepancies may be observed among these different strategies resulting in different treatment strategies. The goal of this study is to assess the feasibility and safety of 68Ga-DOTATATE and to compare it to 123I-MIBG when investigating neuroblastoma.Read full original descriptionShow less
Pilot Study of 68Ga-DOTATATE PET/CT and 123I-MIBG Scintigraphy Imaging of Neuroblastoma
Neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of approximately 10.2 per million children. Staging of the disease can be done by different imaging strategies (CT, MRI, scintigraphy and PET/CT). Discrepancies may be observed among these different strategies resulting in different treatment strategies. The goal of this study is to assess the feasibility and safety of 68Ga-DOTATATE and to compare it to 123I-MIBG when investigating neuroblastoma.
Inclusion: Newly suspected or biopsy-proven neuroblastoma or recurrence of neuroblastoma; Planned 123I-MIBG imaging; Able and willing to provide signed informed consent in French or English (for the adult candidates or the parent/legal tutor of the pediatric candidates); Aged between 1 day and 21 years old (inclusively).
Exclusion: Medical/surgical intervention on the tumour between 123I-MIBG and 68Ga-DOTATATE PET/CT scan; Prior allergic reaction to somatostatin analogues; History of another cancer in the past 5 years other than non-melanomatous skin cancer; Currently under a randomized control trial with unknown allocation; Currently under treatment; Medically unstable or unable to undergo scan; Pregnancy (breastfeeding is not an exclusion criterion but needs to be stopped for at least 12 hours after 68Ga-DOTATATE injection).